Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Jan;27(1):128-34.
doi: 10.1038/modpathol.2013.107. Epub 2013 Jun 14.

Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles

Melissa K McConechy  1 , Jiarui Ding  2 , Janine Senz  1 , Winnie Yang  1 , Nataliya Melnyk  1 , Alicia A Tone  3 , Leah M Prentice  1 , Kimberly C Wiegand  1 , Jessica N McAlpine  4 , Sohrab P Shah  2 , Cheng-Han Lee  5 , Paul J Goodfellow  6 , C Blake Gilks  5 , David G Huntsman  7
Affiliations
Comparative Study

Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles

Melissa K McConechy et al. Mod Pathol. 2014 Jan.

Abstract

Ovarian endometrioid carcinomas and endometrial endometrioid carcinomas share many histological and molecular alterations. These similarities are likely due to a common endometrial epithelial precursor cell of origin, with most ovarian endometrioid carcinomas arising from endometriosis. To directly compare the mutation profiles of two morphologically similar tumor types, endometrial endometrioid carcinomas (n=307) and ovarian endometrioid carcinomas (n=33), we performed select exon capture sequencing on a panel of genes: ARID1A, PTEN, PIK3CA, KRAS, CTNNB1, PPP2R1A, TP53. We found that PTEN mutations are more frequent in low-grade endometrial endometrioid carcinomas (67%) compared with low-grade ovarian endometrioid carcinomas (17%) (P<0.0001). By contrast, CTNNB1 mutations are significantly different in low-grade ovarian endometrioid carcinomas (53%) compared with low-grade endometrial endometrioid carcinomas (28%) (P<0.0057). This difference in CTNNB1 mutation frequency may be reflective of the distinct microenvironments; the epithelial cells lining an endometriotic cyst within the ovary are exposed to a highly oxidative environment that promotes tumorigenesis. Understanding the distinct mutation patterns found in the PI3K and Wnt pathways of ovarian and endometrial endometrioid carcinomas may provide future opportunities for stratifying patients for targeted therapeutics.

PubMed Disclaimer

Conflict of interest statement

Disclosure/Conflict of Interest

The authors have no conflict of interest to disclose.

Figures

Figure 1
Figure 1. Low-grade ovarian and endometrial endometrioid mutation profiles
A. Low-grade endometrial endometrioid carcinomas (EEC) including grade 1 and 2 (n=276). B. Low-grade ovarian endometrioid carcinomas (OEC) including grade 1 and 2 (n=30). Individual columns designate one tumor case, and rows indicate genes. All colored boxes specify a genetic alteration such as missense, truncating, indels, splice site mutations and combinations of these mutations. Grey boxes indicate no mutation were identified by sequencing. These colors are specifically shown in the color legend.
Figure 2
Figure 2. PI3K/AKT and WNT signaling pathways
Theses two signaling pathways show convergence on GSK3β and β-catenin. Genetic alterations caused by mutations in both pathways can result in the transcription of cell growth and proliferation genes. Mutations are indicated by black stars and are found in both ovarian and endometrial endometrioid tumors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Ferlay J, Shin HR, Bray F, et al. International Agency for Research on Cancer. Lyon, France: IARC CancerBase No. 10; 2010. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide. http://globocan.iarc.fr.
    1. Catasus L, Gallardo A, Prat J. Molecular genetics of endometrial carcinoma. Diagnostic Histopathology. 2009;15:554–563.
    1. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int. 2010;2010:162363. - PMC - PubMed
    1. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004;35:649–662. - PubMed

Publication types